Cumberland Pharmaceuticals completed a $100 million strategic transaction with Apotex Health, selling its FDA-approved branded drug portfolio and commercial operations. The deal allows Cumberland to transition into a development-stage biopharmaceutical company focused on rare diseases and unmet medical needs, retaining its late-stage clinical pipeline and majority ownership in Cumberland Emerging Technologies. The company also declared a special dividend to shareholders and reported ongoing losses as it invests in research and development. Cumberland aims to advance its pipeline and explore new strategic opportunities with strengthened financial resources.
Dogecoin has surged past its 200-day moving average, approaching the key $0.10 resistance level after a strong rally from around $0.08. This breakout strengthens its short-term bullish outlook, with technical patterns suggesting potential further gai...
Veteran trader Peter Brandt has revived his 2019 Bitcoin logarithmic chart forecast as BTC trades above $80,000, nearing $82,000 resistance. The model suggests Bitcoin's long-term parabolic uptrend remains intact despite the market's evolution, inclu...
The U.S. Treasury will start an active debt buyback program on Sept. 7, with operations potentially reaching $16.5 billion, aiming to improve market liquidity. This move has drawn attention from cryptocurrency traders as it could support rallies in B...
Bitcoin Blake2 (BTCB2), a fork from the Bitcoin chain split on August 8, 2026, recently hit a price high of $1,799. Despite this surge, BTCB2 faces challenges such as thin liquidity, limited exchange listings on smaller platforms like Neoxa and Nonky...
Robinhood Chain has overtaken Solana in daily decentralized exchange (DEX) volume, processing $1.45 billion compared to Solana's $1.25 billion on September 5. This shift challenges Solana's long-held dominance, as Robinhood also recently crossed $3 b...
